Labetalol

(± )-2- hydroxy-5- { 1-hydroxy- 2-[ (1-methyl -3-phenylpropyl ) amino] ethyl} benzamide

• C19H24N2O3
• C19H24N2O3 · HCl (hydrochloride)

• 36894-69-6
• 32780-64-6 (hydrochloride)

C07AG01

• 328.41 g.mol -1
• 364.87 g.mol -1 (hydrochloride)

• 660 mg · kg -1 ( LD50, Mouse, oral, labetalol )
• > 2000 mg · kg -1 ( LD50, Rat, oral, labetalol )
• 1450 mg · kg -1 ( LD50, Mouse, oral, hydrochloride)
• 2114 mg · kg -1 ( LD50, Rat, oral, hydrochloride)

Template: Infobox chemical / molecular formula search available

Labetalol is a chemical compound selected from the group of salicylic acid derivatives and the benzamide, which is used as a drug for treatment of hypertension ( antihypertensive agents). It acts both as an alpha and beta blockers. The compound was (now GlaxoSmithKline) patented in 1971 by Allen & Hanbury; is used, the more water- soluble and less toxic hydrochloride.

Clinical information

Labetalol has a drug approval for Austria.

Application

Labetalol is in arterial hypertension, both for long-term medication in tablet form as well as intravenously as well as in emergency medicine exclusively iV be used. It acts as an antagonist at both alpha -adrenoceptors and beta -adrenoceptors ( β1 and β2 ).

Side effects

Side effects include, Arterial hypotension, lethargy, insomnia, erectile dysfunction, nausea, discomfort in urination, blurred vision, nasal congestion, and hypersensitivity reactions.

Contraindications

A relative contraindication is given to patients with asthma, congestive heart failure, each blocking the conduction system in the heart ( inter alia SA block and AV block ), bradycardia and cardiogenic shock.

Trade names

Monopreparations: Trandate